Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Симпекс Фарма Пвт. ЛтдfiledCriticalСимпекс Фарма Пвт. Лтд
Priority to UAU201014603UpriorityCriticalpatent/UA61103U/en
Publication of UA61103UpublicationCriticalpatent/UA61103U/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
A pharmaceutical composition for the treatment of multidrug-resistant tuberculosis contains as active ingredients ethambutol hydrochloride and pyrazinamide, protionamid and lomefloxacine hydrochloride, and the components are used in the following ratio, wt.%:Pyrazinamide 0.1-48Ethambutol hydrochloride 0.1-18lomefloxacine hydrochloride 0.1-9.6Protionamid 0.1-24Auxiliary pharmaceutically suitablesubstances up to 100%and the pharmaceutical composition contains at least one layer with the active ingredient, suitable for slow release and ethambutol hydrochloride and protionamid.
UAU201014603U2010-12-062010-12-06pharmaceutical composition for the treatment of multidrug-resistant tuberculosis
UA61103U
(en)
Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
Compounds derived from nitrogenous tricycles, with antibacterial activity; preparation procedure; pharmaceutical composition comprising them; for the treatment of tuberculosis.